TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

121 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Multiple sclerosis (MS)

    Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    Testing remibrutinib in people with relapsing multiple sclerosis who switch from ocrelizumab versus

    📍 Perseverance Research Center · Scottsdale, AZ · +39 more US sites · Get directions →

    The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

    ✓ Study care freePhase 3Ages 40–70Learn more →
  • Multiple sclerosis (MS)

    📍 Novartis Investigative Site · Darlinghurst, New South Wales · Get directions →

    This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • Multiple sclerosis (MS)

    Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    Testing a modified ublituximab treatment for relapsing multiple sclerosis

    📍 TG Therapeutics Investigational Trial Site · Birmingham, AL · +34 more US sites · Get directions →

    The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • High blood pressureKidney disease

    📍 Research Site · Surprise, AZ · +17 more US sites · Get directions →

    International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

    Testing safety of a twice-yearly medicine for early relapsing MS

    📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →

    In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Heart / cardiovascular diseaseKidney disease

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

    Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney

    📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →

    The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

    ✓ Study care freePhase 3Ages 50+Learn more →
  • Multiple sclerosis (MS)

    Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

    Testing whether combining a walking medication with physical therapy improves mobility in people

    📍 MGH Institute of Health Professions · Boston, MA · Get directions →

    The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?

    ✓ Study care freePhase 4Ages 25–75Learn more →
  • Type 2 diabetesHigh blood pressure

    Polypill for Prevention of Cardiomyopathy

    Testing a pill combination to prevent heart muscle disease in people with type 2 diabetes and high

    📍 UT Southwestern Medical Center · Dallas, TX · Get directions →

    This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily.

    ✓ Study care freePhase 1Ages 18–100Learn more →
  • Sickle cell disease

    A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

    Testing the safety and how an oral carbon monoxide liquid works in sickle cell disease

    📍 Cevaxin - The Panama Clinic · Panama City, · Get directions →

    This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • Sickle cell disease

    Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

    Testing whether a low dose of ketamine helps treat sickle cell pain in children and young adults

    📍 Harbor UCLA Medical Center · Torrance, CA · Get directions →

    The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.

    ✓ Study care freePhase 2Ages 5–20Learn more →
  • Sickle cell disease

    The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

    Testing rilzabrutinib for safety and effectiveness in sickle-cell disease

    📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +15 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B).

    ✓ Study care freePhase 3Ages 10–65Learn more →
  • Multiple sclerosis (MS)

    A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    Testing a drug called BMS-986368 for muscle stiffness in multiple sclerosis

    📍 Alabama Neurology Associates · Birmingham, AL · +14 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

    ✓ Study care freePhase 2Ages 18–70Learn more →
  • Multiple sclerosis (MS)

    A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    Testing a drug called orelabrutinib versus placebo in people with PPMS

    📍 Arizona Neuroscience Research, LLC · Pheonix, AZ · +12 more US sites · Get directions →

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.

    ✓ Study care freePhase 3Ages 18–60Learn more →
  • Multiple sclerosis (MS)

    A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

    Checking if two under-the-skin versions of ocrelizumab match in the body in people with multiple

    📍 Profound Research, LLC · Carlsbad, CA · +8 more US sites · Get directions →

    The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Obesity / overweightHigh blood pressure

    Impact GLP-1 Agonists Following Bariatric

    Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar

    📍 University of Missouri Hospital · Columbia, MO · Get directions →

    Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Sickle cell disease

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

    Testing whether extra arginine lowers pain in children with sickle cell

    📍 Children's Healthcare fo Atlanta at Hughes Spalding · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

    ✓ Study care freePhase 1Ages 7–21Learn more →
  • Multiple sclerosis (MS)

    Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

    Testing whether corticosteroids change inflammation in acute MS lesions

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways.

    ✓ Study care freePhase 2Ages 18–120Learn more →
  • Multiple sclerosis (MS)

    Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

    Comparing stem cell transplant vs best available treatment for relapsing multiple sclerosis

    📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · +21 more US sites · Get directions →

    This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.

    ✓ Study care freePhase 3Ages 18–55Learn more →
  • Sickle cell disease

    A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

    Testing a once-daily mouth medicine in teens with sickle cell disease

    📍 The Hospital for Sick Children · Toronto, Ontario · Get directions →

    This study is being done to learn about etavopivat, a once a day medicine taken by mouth in adolescents with sickle cell disease. The main goals are to study safety and how long etavopivat stays in the bloodstream, while also studying if there are benefits from taking etavopivat.

    ✓ Study care freePhase 2Ages 1–18Learn more →
  • Heart / cardiovascular disease

    Improving Coronary Vascular Health in Women

    Testing whether blood flow in heart arteries can be improved in women with HIV

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed.

    ✓ Study care freePhase 2Ages 45–75WomenLearn more →
  • Multiple sclerosis (MS)

    Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

    Testing solriamfetol to treat tiredness from multiple sclerosis

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness.

    ✓ Study care freePhase 2Ages 18–60Learn more →
  • Multiple sclerosis (MS)

    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    Testing orelabrutinib versus placebo for people with non-active secondary progressive multiple

    📍 Arizona Neuroscience Research, LLC · Phoenix, AZ · +12 more US sites · Get directions →

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS.

    ✓ Study care freePhase 3Ages 18–60Learn more →
  • Sickle cell disease

    RH Genotype Matched RBC Transfusions

    Testing whether matching donor red blood cells by RH type helps people with sickle cell who need

    📍 Children's Hospital of Philadelphia · Philadelphia, PA · Get directions →

    To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

    ✓ Study care freePhase 1Ages 1+Learn more →
  • Heart / cardiovascular diseaseHigh blood pressure

    EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

    Testing a drug taken with empagliflozin in adults with type 2 diabetes and heart disease

    📍 Pinnacle Research Group, LLC · Anniston, AL · +39 more US sites · Get directions →

    This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Home Based Infusions for Ocrelizumab

    Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis

    📍 Amerita · Centennial, CO · Get directions →

    The goal is to assess the safety and effectiveness of home ocrelizumab infusion.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • High blood pressureCOPD (chronic lung disease)

    Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

    Testing tadalafil to see if it improves shortness of breath in COPD with high blood pressure in the

    📍 Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, CO · +4 more US sites · Get directions →

    The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function.

    ✓ Study care freePhase 2Ages 35–89Learn more →
  • Multiple sclerosis (MS)

    📍 Local Institution - 0114 · Loma Linda, CA · +11 more US sites · Get directions →

    The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

    ✓ Study care freePhase 3Ages 10–17Learn more →
  • Multiple sclerosis (MS)

    Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

    Testing whether TRX319 is safe for people with progressive multiple sclerosis

    📍 University of Kansas Medical Center · Kansas City, KS · +1 more US site · Get directions →

    The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS?

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

    Testing a one-time blood stem cell transplant using gene editing for severe sickle cell disease

    📍 University of California, Los Angeles · Los Angeles, CA · +1 more US site · Get directions →

    This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR\_SCD001 Drug Product).

    ✓ Study care freePhase 1Ages 12–35Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Testing a medicine to reduce brain and eye tissue loss in people with multiple sclerosis

    📍 Johns Hopkins University · Baltimore, MD · +1 more US site · Get directions →

    The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).

    ✓ Study care freePhase 2Ages 18–60Learn more →
  • Sickle cell disease

    Cannabidiol in Sickle Cell Disease

    Testing twice-daily cannabidiol doses for people with sickle cell disease

    📍 Icahn School of Medicine at Mount Sinai · Manhattan, NY · Get directions →

    Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

    Testing whether special MRI using hyperpolarized carbon can predict how relapsing-remitting MS

    📍 Byers Hall · San Francisco, CA · Get directions →

    The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy. Study procedures will include magnetic resonance imaging (MRI) assessments with a hyperpolarized pyruvate sequence, clinical assessment as well as blood markers of disease progression.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • High blood pressure

    📍 Sarfez Pharmaceuticals, Inc. · Vienna, VA · Get directions →

    A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Multiple sclerosis (MS)

    A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    Testing how well and how safely remibrutinib works in secondary progressive multiple sclerosis

    📍 Alabama Neurology Associates PC · Birmingham, AL · +32 more US sites · Get directions →

    The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Sickle cell disease

    Early Screening and Treatment of Heart Complication in Sickle Cell Disease

    Testing early heart screening and iron overload treatment in people with sickle cell disease

    📍 Inova Schar Cancer · Fairfax, VA · +1 more US site · Get directions →

    This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Sickle cell disease

    Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

    Testing whether routine red blood cell transfusions in pregnancy reduce sickle cell flare-ups or

    📍 Grady Health System · Atlanta, GA · Get directions →

    The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Sickle cell disease

    Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

    Testing two daily doses of zinc in people with sickle cell disease to see changes in bone-related

    📍 UCSF Benioff Children's Hospital Oakland · Oakland, CA · +5 more US sites · Get directions →

    The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-40 years old. The main question it aims to answer is: Which biomarkers are most responsive to zinc supplementation, and what is the maximum tolerated zinc dose that induces the desired changes in biomarkers of bone turnover?

    ✓ Study care freePhase 2Ages 15–40Learn more →
  • Sickle cell disease

    Allo HSCT for High Risk Hemoglobinopathies

    Testing donor stem cell transplant for people with high-risk sickle cell

    📍 Masonic Cancer Center · Minneapolis, MN · Get directions →

    A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.

    ✓ Study care freePhase 2Learn more →
  • Sickle cell disease

    Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

    Testing a single pneumococcal vaccine dose in children with sickle cell disease

    📍 Site # 8400006 · Atlanta, GA · +4 more US sites · Get directions →

    The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • High blood pressureDementia / Alzheimer's

    Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

    Testing whether tightly lowering high blood pressure slows brain changes tied to Alzheimer’s

    📍 University of Texas Southwestern Medical Center · Dallas, TX · Get directions →

    The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.

    ✓ Study care freePhase 2Ages 60–85Learn more →
  • Multiple sclerosis (MS)

    Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

    Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis

    💵 May compensate

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →

    A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Heart / cardiovascular diseaseLupus (SLE)

    The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

    Testing whether anifrolumab improves blood vessel risk markers in lupus

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Multiple sclerosis (MS)

    Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

    Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    Testing whether maridebart cafraglutide lowers heart risks in people with heart disease and obesity

    📍 Alliance For Multispecialty Research - Daphne · Daphne, AL · +39 more US sites · Get directions →

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    ✓ Study care freePhase 3Ages 45–99Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    Testing maridebart cafraglutide with standard care to reduce heart failure events in obese people

    💵 May compensate

    📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).

    ✓ Study care freePhase 3Ages 18–99Learn more →
  • Multiple sclerosis (MS)

    Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

    Testing metformin alone or with other treatment in older people with multiple sclerosis

    📍 UBMD Neurolgy · Buffalo, NY · Get directions →

    The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy.

    ✓ Study care freePhase 2Ages 55–75Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    Testing how well NNC0487-0111 works versus placebo in heart failure with excess body weight

    📍 Advanced Cardiovascular, LLC · Alexander City, AL · +39 more US sites · Get directions →

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Obesity / overweightHigh blood pressure

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Testing treatments to lower high pressure in liver veins in people with advanced liver disease and

    💵 May compensate

    📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →

    Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Sickle cell disease

    A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

    Testing immune-suppressing treatment before stem cell transplant for people with sickle cell disease

    📍 Memorial Sloan Kettering at Basking Ridge (Consent only) · Basking Ridge, NJ · +5 more US sites · Get directions →

    Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers think giving participants treatment with fludarabine and dexamethasone, drugs that lower the activity of the body's immune system (immune suppression), before standard conditioning therapy and HCT may help prevent serious side effects, including graft failure and GvHD.

    ✓ Study care freePhase 2Ages 2–50Learn more →
  • Obesity / overweightHigh blood pressureCOPD (chronic lung disease)

    Feasibility of Semaglutide in Advanced Lung Disease

    Testing whether semaglutide can be given safely to people with advanced lung disease

    📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →

    The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Sickle cell disease

    A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

    Testing long-term treatment with a new medicine for sickle cell or thalassaemia

    📍 Univ of Alabama Birmingham · Birmingham, AL · +38 more US sites · Get directions →

    Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin.

    ✓ Study care freePhase 3Ages 2+Learn more →
  • Sickle cell disease

    A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

    Testing how BMS-986470 affects the body and safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +18 more US sites · Get directions →

    The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Glucose Consumption in MS Using [F-18]FDG-PET

    Testing how [F-18]FDG PET shows glucose use in people with MS and controls

    📍 Brigham & Women's Hospital · Boston, MA · Get directions →

    Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS (PMS) and relapsing-remitting MS (RRMS), as well as healthy controls.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Sickle cell disease

    Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

    Testing a partial stem cell transplant from matched donors for severe sickle cell disease or

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens.

    ✓ Study care freePhase 1Ages 4–65Learn more →
  • Sickle cell disease

    Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

    Testing empagliflozin to treat kidney disease related to sickle cell

    📍 University of Illinois Chicago, Sickle Cell Center · Chicago, IL · Get directions →

    Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA.

    ✓ Study care freePhase 2Ages 18–60Learn more →
  • Sickle cell disease

    Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

    Testing a transplant plan with daratumumab to reduce blood cell failure in sickle cell disease

    📍 Children's National Hospital · Washington D.C., DC · Get directions →

    This multicenter prospective study seeks to determine if daratumumab given, prior to HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus, can prevent pure red blood cell aplasia with an acceptable safety profile in patients with anti-donor red blood cell antibodies, achieving an event-free survival similar to transplanted patients without such antibodies.

    ✓ Study care freePhase 2Ages 2–25Learn more →
  • Multiple sclerosis (MS)

    Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

    Testing whether silodosin helps lower urinary tract symptoms in women with multiple sclerosis

    📍 Atlantic Health · Morristown, NJ · Get directions →

    The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Multiple sclerosis (MS)

    Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

    Testing whether clemastine fumarate changes MRI signs of nerve repair in people with multiple

    📍 Sandler Neurosciences Building, Neurological Clinical Research Unit · San Francisco, CA · Get directions →

    The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments. No reparative therapies exist for the treatment of multiple sclerosis.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • Multiple sclerosis (MS)

    Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

    Testing a nasal treatment in people with non-active secondary progressive multiple sclerosis

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients are eligible to be enrolled in TILS-022. TILS-022 is a 6-month open-label extension study with an opportunity for dose to be escalated based on the subject's clinical status.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Showing the first 60 of 121. Add filters or a location to narrow down.